Seer names Charles Endweiss finance chief: what it means for Seer stock

Published on 10/05/2026 at 19:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Seer posted USD 3.10 million in second-quarter 2026 revenue, down 23.00 percent. For Seer stock this means USD 16.00-18.00 million revenue.

SEER, US81578P1066, Illustration mit AI erstellt.

Seer (US81578P1066) named Charles Endweiss principal financial officer and principal accounting officer effective October 1, 2026, after David Horn resigned as president, chief financial officer and treasurer. The leadership change gives investors a fresh reference point while the company works through declining quarterly revenue and substantial operating losses.

New finance chief takes over

MarketScreener reported on September 18, 2026 that Omid Farokhzad would add the president role to his existing positions as chief executive officer and board chair, while Endweiss would assume the finance leadership duties. Horn's resignation was described as unrelated to a disagreement about company operations.

The transition arrives as Seer commercializes its Proteograph platform for large-scale protein analysis. The company had 124 full-time employees in the latest company profile, and its business spans consumables, automated instruments and software for research applications.

Revenue outlook faces a test

StockTitan reported that Seer generated USD 3.10 million of revenue in the second quarter of 2026, down 23.00 percent from the year-earlier quarter. Net loss was USD 16.90 million, while gross margin stood at 49.00 percent in the same period.

The company reaffirmed 2026 revenue guidance of USD 16.00 million to USD 18.00 million. That outlook places execution at the center of the story because the second-quarter revenue run rate was below the full-year midpoint required for a meaningful acceleration later in the year.

Seer ended June 30, 2026 with USD 209.50 million in cash, cash equivalents and investments, according to StockTitan. That liquidity provides a measurable counterweight to the USD 16.90 million quarterly net loss, although operating cash flow remained negative at USD 9.57 million in the second quarter.

What the transition means

The immediate investor test is whether the new finance team can convert the Proteograph platform's scientific traction into the USD 16.00 million to USD 18.00 million revenue range for 2026. A revenue decline of 23.00 percent in the second quarter makes that target more demanding than the headline guidance alone suggests.

MarketBeat reported on October 5, 2026 that one analyst consensus rating was Buy with an average target of USD 4.00. The same report listed short interest of 87,329 shares as of September 15, equal to 0.20 percent of shares outstanding.

Market value and listing

Seer had a market capitalization of USD 127.8 million on October 5, 2026. Its primary listing is Nasdaq under ticker SEER, and the 52-week range was USD 1.55 to USD 2.41 on that date.